Two things:
Firstly, Val's latest PCR last week was 0.001 - we have taken to saying it is better than 007! We couldn't be happier about that result and we celebrated with a bottle of champagne!
Secondly, Val has been asked to make her medical records at the Hammersmith available for a new study. The purpose of the study is to collect information about patients with CML and the treatments they receive in order to estimate how many patients experience resistance or intolerance to their treatment in the various phases of the disease. The study is to be performed in 8 countries in Europe during 2006 and aims to evaluate about 2,600 patients in total. A team of experts will look at the data to better understand how CML is managed in Europe. The study is funded by Bristol-Myers Squibb, Belgium. Val has agreed and asked if she can have a copy of the study on completion.
David Cornes